天士力：终止与Arbor公司合作，收回产品美国独家销售权

Core Viewpoint - The company has terminated its licensing agreement with Arbor due to Arbor's acquisition by Azurity and subsequent business adjustments, regaining exclusive sales rights for a specific product in the U.S. market [1] Group 1: Agreement Details - The company signed a licensing agreement with Arbor in 2018, granting exclusive sales rights for Compound Danshen Dripping Pills in the U.S. [1] - The termination agreement was mutually agreed upon following Arbor's acquisition and business restructuring by Azurity [1] Group 2: Financial Impact - The company will receive a payment of $7.5 million as part of the termination of the agreement [1] - The termination of the partnership is not expected to have a significant impact on the company's project advancement, production operations, or financial status [1]